GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Magenta Therapeutics Inc (NAS:MGTA) » Definitions » ROIC %

Magenta Therapeutics (Magenta Therapeutics) ROIC % : 0.00% (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Magenta Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Magenta Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was 0.00%.

As of today (2024-05-13), Magenta Therapeutics's WACC % is 5.99%. Magenta Therapeutics's ROIC % is -163.53% (calculated using TTM income statement data). Magenta Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Magenta Therapeutics ROIC % Historical Data

The historical data trend for Magenta Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Magenta Therapeutics ROIC % Chart

Magenta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROIC %
Get a 7-Day Free Trial -855.21 -681.89 -686.78 -730.73 -362.28

Magenta Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -195.77 -191.30 -246.56 -162.07 -

Competitive Comparison of Magenta Therapeutics's ROIC %

For the Biotechnology subindustry, Magenta Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Magenta Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Magenta Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Magenta Therapeutics's ROIC % falls into.



Magenta Therapeutics ROIC % Calculation

Magenta Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-80.902 * ( 1 - 0% )/( (9.796 + 34.867)/ 2 )
=-80.902/22.3315
=-362.28 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=146.645 - 10.725 - ( 112.041 - max(0, 14.549 - 115.602+112.041))
=34.867

Magenta Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2023 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-21.828 * ( 1 - 0% )/( (0 + 0)/ 2 )
=-21.828/0
= %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Magenta Therapeutics  (NAS:MGTA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Magenta Therapeutics's WACC % is 5.99%. Magenta Therapeutics's ROIC % is -163.53% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Magenta Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Magenta Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Magenta Therapeutics (Magenta Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Technology Square, 5th Floor, Cambridge, MA, USA, 02139
Magenta Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy. The pipeline of the company includes MGTA-117, MGTA-145, MGTA-45 and others.
Executives
Peter Evan Harwin director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Tomas Kiselak director, 10 percent owner 2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc director, 10 percent owner 200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Edward Carr officer: CHIEF ACCOUNTING OFFICER 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Ryan Savitz officer: CHIEF FINANCIAL OFFICER 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Lei Meng director 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Simrat Randhawa officer: Chief Medical Officer 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Avidity Partners Management Lp director 2828 N HARWOOD STREET, SUITE 1220, DALLAS TX 75201
Marino Garcia director, officer: CEO and President C/O SYNERGY PHARMACEUTICALS INC., 420 LEXINGTON AVENUE, SUITE 2012, NEW YORK NY 10170
Adam M Veness officer: See Remarks C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK NY 10036
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paula Soteropoulos director 49 WINONA STREET, PEABODY MA 01960
Jonathan Violin director 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Michael Vasconcelles director C/O UNUM THERAPEUTICS, 200 CAMBRIDGEPARK DR., STE. 3100, CAMBRIDGE MA 02140

Magenta Therapeutics (Magenta Therapeutics) Headlines

From GuruFocus

Magenta Therapeutics to Explore Strategic Alternatives

By Stock market mentor Stock market mentor 02-02-2023